Last reviewed · How we verify
Administration of Vancomycin
Administration of Vancomycin is a Glycopeptide antibiotic Small molecule drug developed by University of Colorado, Denver. It is currently FDA-approved for Serious infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile-associated diarrhea and colitis, Endocarditis caused by susceptible streptococci or staphylococci. Also known as: Vancomycin Hydrochloride.
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptide precursors and preventing peptidoglycan cross-linking.
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptide precursors and preventing peptidoglycan cross-linking. Used for Serious infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile-associated diarrhea and colitis, Endocarditis caused by susceptible streptococci or staphylococci.
At a glance
| Generic name | Administration of Vancomycin |
|---|---|
| Also known as | Vancomycin Hydrochloride |
| Sponsor | University of Colorado, Denver |
| Drug class | Glycopeptide antibiotic |
| Target | D-Ala-D-Ala peptidoglycan precursor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls, blocking the cross-linking of peptidoglycan strands. This disrupts cell wall integrity and leads to bacterial cell lysis and death. It is bactericidal and particularly effective against gram-positive organisms.
Approved indications
- Serious infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)
- Clostridium difficile-associated diarrhea and colitis
- Endocarditis caused by susceptible streptococci or staphylococci
- Septicemia caused by susceptible gram-positive cocci
Common side effects
- Nephrotoxicity
- Ototoxicity
- Red man syndrome (flushing, pruritus)
- Phlebitis at infusion site
- Fever
- Chills
Key clinical trials
- Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children (NA)
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
- IO Vancomycin Spine (PHASE2, PHASE3)
- Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection (NA)
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial (PHASE4)
- Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of Vancomycin CI brief — competitive landscape report
- Administration of Vancomycin updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI
Frequently asked questions about Administration of Vancomycin
What is Administration of Vancomycin?
How does Administration of Vancomycin work?
What is Administration of Vancomycin used for?
Who makes Administration of Vancomycin?
Is Administration of Vancomycin also known as anything else?
What drug class is Administration of Vancomycin in?
What development phase is Administration of Vancomycin in?
What are the side effects of Administration of Vancomycin?
What does Administration of Vancomycin target?
Related
- Drug class: All Glycopeptide antibiotic drugs
- Target: All drugs targeting D-Ala-D-Ala peptidoglycan precursor
- Manufacturer: University of Colorado, Denver — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Serious infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)
- Indication: Drugs for Clostridium difficile-associated diarrhea and colitis
- Indication: Drugs for Endocarditis caused by susceptible streptococci or staphylococci
- Also known as: Vancomycin Hydrochloride
- Compare: Administration of Vancomycin vs similar drugs
- Pricing: Administration of Vancomycin cost, discount & access